StemCell Therapy

SANTA ANA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), today announced it received a notice (the “Notice”) on November 20, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) because it had not timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”) on or before November 19, 2024, the extended period provided for the filing under Rule 12b-25(b) of the Securities Exchange Act of 1934, as amended. The delay is in part due to the additional time required for valuation and review of various derivative securities as the Company has taken on more reporting responsibility internally. The Notice from Nasdaq has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market.

See the rest here:
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

DURHAM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Evercore HealthCONx Conference on Thursday, December 5, 2024 at 10:00 am ET.

View post:
Fortrea to Present at the Evercore HealthCONx Conference

PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC.

Visit link:
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference

WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York.

Follow this link:
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace in New York City.

More:
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

Ad hoc announcement pursuant to Art. 53 LR

More:
Idorsia enters into exclusive negotiations for global rights to aprocitentan

Basel, November 27, 2024 – Novartis announced today that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence1,7.

Go here to read the rest:
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE27 NOVEMBER 2024 at 9.00 EET

Link:
142,701 Orion Corporation A shares converted into B shares

Unraveling The Complexity Of Cell Therapy: Advancements And Challenges  Life Science Leader Magazine

See the rest here:
Unraveling The Complexity Of Cell Therapy: Advancements And Challenges - Life Science Leader Magazine

Novartis wagers more than $1B on gene therapies for the nervous system  BioPharma Dive

See the original post:
Novartis wagers more than $1B on gene therapies for the nervous system - BioPharma Dive

Gene therapy for geographic atrophy in age-related macular degeneration: current insights  Nature.com

Read the original here:
Gene therapy for geographic atrophy in age-related macular degeneration: current insights - Nature.com

Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment  STAT

Continued here:
Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - STAT

At MGB's gene therapy institute, effort to win first venture capital investments continues  The Business Journals

See more here:
At MGB's gene therapy institute, effort to win first venture capital investments continues - The Business Journals

Neurogene reports death of Rett patient left in critical condition by high dose of gene therapy  Fierce Biotech

See more here:
Neurogene reports death of Rett patient left in critical condition by high dose of gene therapy - Fierce Biotech

Alzheimer Disease Awareness Month 2024: Looking Back at a Year of Progress in Cell and Gene Therapy  CGTLive

View original post here:
Alzheimer Disease Awareness Month 2024: Looking Back at a Year of Progress in Cell and Gene Therapy - CGTLive

Why This Gene-Therapy Companys Stock Is Rising 228%  Yahoo! Voices

Read more:
Why This Gene-Therapy Companys Stock Is Rising 228% - Yahoo! Voices

How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando  geneonline

The rest is here:
How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando - geneonline

RNA editing is the next frontier in gene therapy heres what you need to know  The Conversation

The rest is here:
RNA editing is the next frontier in gene therapy heres what you need to know - The Conversation

Assessment of gene therapy viral vectors in RPE cells  News-Medical.Net

See the original post here:
Assessment of gene therapy viral vectors in RPE cells - News-Medical.Net

Retinal organoids and RPE models for retinal gene therapy development  News-Medical.Net

Link:
Retinal organoids and RPE models for retinal gene therapy development - News-Medical.Net